Overview
Akimichi Ohsaka practices in Tokyo, Japan. Ohsaka is rated as an Advanced expert by MediFind in the treatment of Myelofibrosis. Their top areas of expertise are Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Polycythemia Vera, and Philadelphia-Negative Chronic Myeloid Leukemia.
Their clinical research consists of co-authoring 74 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 8 articles in the study of Myelofibrosis.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Essential ThrombocythemiaOhsaka isAdvanced. Learn about Essential Thrombocythemia.
- MyelofibrosisOhsaka isAdvanced. Learn about Myelofibrosis.
- Myeloproliferative Neoplasms (MPN)
- Philadelphia-Negative Chronic Myeloid Leukemia
- Polycythemia VeraOhsaka isAdvanced. Learn about Polycythemia Vera.
- Experienced
- Acute Erythroid Leukemia (AEL)Ohsaka isExperienced. Learn about Acute Erythroid Leukemia (AEL).
- AnemiaOhsaka isExperienced. Learn about Anemia.
- Aplastic AnemiaOhsaka isExperienced. Learn about Aplastic Anemia.
- Blood ClotsOhsaka isExperienced. Learn about Blood Clots.
- Chronic Myelogenous Leukemia (CML)
- Hemolytic Transfusion ReactionOhsaka isExperienced. Learn about Hemolytic Transfusion Reaction.